Collij, Lyduine E.Bollack, ArianeLa Joie, RenaudShekari, MahnazBullich, SantiagoRoé Vellvé, NúriaKoglin, NormanJovalekic, AleksandarVállez García, DavidDrzezga, AlexanderGaribotto, ValentinaStephens, Andrew W.Battle, MarkBuckley, Christopher, 1948-Barkhof, FrederikFarrar, GillGispert López, Juan DomingoAMYPAD Consortium2025-09-292025-09-292024Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024 Dec;20(12):9037-48. DOI: 10.1002/alz.143361552-5260http://hdl.handle.net/10230/71286Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs ("intermediate range") are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. HIGHLIGHTS: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ-negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid-PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.application/pdfeng© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/alz.14336Amyloid‐βCentiloid quantificationClinical trialsPositron emission tomographyinfo:eu-repo/semantics/openAccess